Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Jan‐Peter Sowa(Universitätsklinikum Knappschaftskrankenhaus Bochum), Ali Canbay(Universitätsklinikum Knappschaftskrankenhaus Bochum), K. Lackner(Medical University of Graz), Norbert Scherbaum(Klinik und Poliklinik für Psychiatrie und Psychotherapie), Svenja Sydor(Universitätsklinikum Knappschaftskrankenhaus Bochum), Martin Schlattjan(University of Duisburg-Essen), Özgür Atmaca(Hacettepe University Hospital), Alişan Kahraman(University of Duisburg-Essen), Gavin E. Arteel(University of Pittsburgh), Dominik Heider(Philipps University of Marburg), Marion Lindner(University of Duisburg-Essen), Yeşim Erim(Friedrich-Alexander-Universität Erlangen-Nürnberg), Guido Gerken
Cited by 55
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
|International Journal of Cancer|2010|520
Toll–Like Receptor 4 Is Involved in the Mechanism of Early Alcohol–Induced Liver Injury in Mice
|Hepatology|2001|487
Oxidants and antioxidants in alcohol-induced liver disease
|Gastroenterology|2003|485